Your PD-L1 Score: What It Is and How It Determines Head and Neck Cancer Treatment

A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.
Targeted Oncology

Checkpoint Inhibitors in Lung Cancer: When One Drug Isn't Enough

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Medscape

PD-L1 Did Not Predict Immunotherapy Benefit in Cervical Cancer

Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...
The American Journal of Managed Care

Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% ...
Pharm Exec

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...